Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 Aug;27(8):e70106.
doi: 10.1111/jch.70106.

Comparison of Globorisk, SCORE2, and PREVENT in the Stratification of Cardiovascular Risk and its Relationship with End-Organ Damage Among Adults With Arterial Hypertension

Affiliations
Comparative Study

Comparison of Globorisk, SCORE2, and PREVENT in the Stratification of Cardiovascular Risk and its Relationship with End-Organ Damage Among Adults With Arterial Hypertension

Silvia Palomo-Piñón et al. J Clin Hypertens (Greenwich). 2025 Aug.

Abstract

Arterial hypertension often coexists with comorbidities that increase vascular damage. Although the primary goal is to reduce cardiovascular risk, the available risk scores can produce varying estimates. Here, we aim to compare the prevalence of cardiovascular risk categories using three equations (Globorisk, SCORE2, and PREVENT) in adults living with arterial hypertension and to assess their association as stratification tools for end-organ damage (EOD). To achieve this, we performed a cross-sectional sub-analysis of the RIHTA study, an electronic health record-based registry of adults with arterial hypertension in Mexican primary care centers. EOD was defined as aortic stiffness, reduced eGFR, hypertensive retinopathy, peripheral artery disease, or left ventricular hypertrophy. Inverse probability weighting (IPW) was used to evaluate the association between cardiovascular risk and EOD, adjusting for relevant confounders, and areas under the receiver operator curve (AUROC) were calculated to assess detection capacity. Among 4512 participants (median age 64 years; 61% women), EOD was present in 33% (n = 1492). The PREVENT equation yielded the highest median 10-year risk (15%, IQR 8-24), followed by Globorisk laboratory-based (12%, 7-22), Globorisk office-based (11%, 7-19), and SCORE2 (5.06%, 3.86-7.18). In IPW models, each 1% increase in score was associated with higher odds of EOD (PREVENT OR 1.16, 95% CI 1.15-1.17; Globorisk-office 1.09, 1.08-1.10; Globorisk-lab 1.07, 1.06-1.08; SCORE2 1.04, 1.02-1.06). The PREVENT score demonstrated the strongest discrimination for detecting EOD (AUROC: 0.751, 0.735-0.750). These findings suggest that among adults with arterial hypertension, the PREVENT score identifies high-risk individuals and improves discrimination for EOD.

Keywords: Mexico; arterial hypertension; cardiovascular risk; end‐organ damage; epidemiology.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

FIGURE 1
FIGURE 1
STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) flowchart of our studied population.
FIGURE 2
FIGURE 2
Prevalence of CVD risk categories among women and men. Error bars represent 95% confidence intervals.
FIGURE 3
FIGURE 3
Prevalence of CVD risk categories stratified by blood pressure control (<130/80 and ≥130/80 mm Hg) among women and men. Error bars represent 95% confidence intervals.
FIGURE 4
FIGURE 4
ROC curves for CVD risk prediction models among women (A) and men (B). The area under the receiver operator curve (AUROC) and corresponding 95% confidence intervals are displayed in the table inset.

Similar articles

References

    1. Tapia‐Conyer R., Alegre‐Díaz J., Gnatiuc L., et al., “Association of Blood Pressure With Cause‐Specific Mortality in Mexican Adults,” JAMA Network Open 3, no. 9 (2020): e2018141. - PMC - PubMed
    1. Global Cardiovascular Risk Consortium , Magnussen C., Ojeda F. M., et al., “Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality,” New England Journal of Medicine 389, no. 14 (2023): 1273–1285. - PMC - PubMed
    1. Fuchs F. D. and Whelton P. K., “High Blood Pressure and Cardiovascular Disease,” Hypertension Dallas Tex 1979 75, no. 2 (2020): 285–292. - PMC - PubMed
    1. Parati G., Lombardi C., Pengo M., Bilo G., and Ochoa J. E., “Current Challenges for Hypertension Management: From Better Hypertension Diagnosis to Improved Patients' Adherence and Blood Pressure Control,” International Journal of Cardiology 331 (2021): 262–269. - PubMed
    1. Schutte A. E., Venkateshmurthy N. S., Mohan S., and Prabhakaran D., “Hypertension in Low‐ and Middle‐Income Countries,” Circulation Research 128, no. 7 (2021): 808–826. - PMC - PubMed

Publication types

MeSH terms